



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/00, A01K 67/027 C12N 5/10, C07K 15/00	A1	(11) International Publication Number: WO 93/14200 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/US92/11276 (22) International Filing Date: 29 December 1992 (29.12.92) (30) Priority data: 817,584 7 January 1992 (07.01.92) US 915,469 16 July 1992 (16.07.92) US (71) Applicant: TSI CORPORATION [US/US]; Innovation Drive, Worcester, MA 01605 (US). (72) Inventors: WADSWORTH, Samuel ; 12 Ferncroft Road, Shrewsbury, MA 01545 (US). SNYDER, Benjamin ; 20 Cedar Street, Worcester, MA 01609 (US). REDDY, Vermuri, B. ; 3 McTaggart Street, Westborough, MA 01581 (US). WEI, Cha-Mer ; 1101 Old Connecticut Path, Framingham, MA 01701 (US).		(74) Agents: PABST, Patrea, L. et al.; Kilpatrick & Cody, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309-4530 (US). (81) Designated States: AU, CA, FI, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TRANSGENIC ANIMAL MODELS FOR ALZHEIMER'S DISEASE (57) Abstract <p>The construction of transgenic animal models for testing potential treatments for Alzheimer's disease are described. The models are characterized by a greater similarity to the conditions existing in naturally occurring Alzheimer's disease, based on expression of all three forms of the β-amyloid precursor protein (APP), APP₆₉₅, APP₇₅₁, and APP₇₇₀, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, and predicted mutations in the APP gene. The APP gene constructs are prepared using the naturally occurring promoter, as well as inducible promoters such as the mouse metallothionein promoter, which can be regulated by addition of heavy metals such as zinc to the animal's water or diet, and promoters such as the rat neuron specific enolase promoter, human β actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter. The constructs are introduced into animal embryos using standard techniques such as microinjection. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount and histopathology of APP and β-amyloid peptide in the animals, as well as by behavioral alterations.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

Transgenic Animal Models for Alzheimer's Disease

Background of the Invention

Transgenic technology is described for the production of animals that exhibit symptoms of human Alzheimer's disease through the expression of the Alzheimer's precursor protein or a modified version thereof.

Alzheimer's Disease (AD) is a degenerative disorder of the brain first described by Alois Alzheimer in 1907 after examining one of his patients who suffered drastic reduction in cognitive abilities and had generalized dementia ("The early story of Alzheimer's Disease", edited by Bick K., Amaducci L., and Pepeu G. (Raven Press, New York 1987). It is the leading cause of dementia in elderly persons. AD patients have increased problems with memory loss and intellectual functions which progress to the point where they cannot function as normal individuals. With the loss of intellectual skills the patients exhibit personality changes, socially inappropriate actions and schizophrenia ("A guide to the understanding of Alzheimer's Disease and related disorders", edited by Jorm AF.; (New York University Press, New York 1987). AD is devastating for both victims and their families, for there is no effective palliative or preventive treatment for the inevitable neurodegeneration. The most common problems in the Alzheimer's patient are inability to dress unaided, restlessness by day, urinary incontinence and sleep

The family members report

-2-

annual cost of \$40 billion (Jorm, 1987; Fisher, LM: New York Times, August 23, 1989 D1 "Alzheimer's Disease", edited by Reisberg, B.; (The Free Press, New York & London 1983). These factors imply preventive action must be taken to decrease AD incidence by allocating resources into AD research.

At a macroscopic level, the brains of AD patients are usually smaller, sometimes weighing less than 1,000 grams. At a microscopic level, the histopathological symptoms of AD include neurofibrillary tangles (NFT), neuritic plaques, and degeneration of neurons. AD patients exhibit degeneration of nerve cells in the frontal and temporal cortex of the cerebral cortex, pyramidal neurons of hippocampus, neurons in the medial, medial central, and cortical nuclei of the amygdala, noradrenergic neurons in the locus coeruleus, and the neurons in the basal forebrain cholinergic system. Loss of neurons in the cholinergic system leads to a consistent deficit in cholinergic presynaptic markers in AD (Reisberg, 1983; "Alzheimer's Disease and related disorders, research and development" edited by Kelly WE; (Charles C. Thomas, Springfield, IL. 1984).

AD is associated with neuritic plaques measuring up to 200 μ m in diameter in the cortex, hippocampus, subiculum, hippocampal gyrus, and amygdala. One of the principal constituents of neuritic plaques is

-3-

neuropathy. However, available evidence strongly indicates two distinct types of genetic predisposition for AD. First, molecular analysis has provided evidence for mutations in the amyloid precursor protein (APP) gene in certain AD-stricken families (Goate, et al. Nature 349:704-706 (1991); Murrell, J, et al. Science 254; 97-99, 1991; Chartier-Harlin, M-C, et al. Nature 353, 844-846 (1991)). Second, in certain other families with a clear genetic predisposition to AD, the mutation maps to chromosome 21 but is distinct from the APP locus (Tanzi, R.E., et al. Nature, 331;528-530 (1988)).

Amyloid plaques are abundantly present in AD patients and in Down's Syndrome individuals surviving to the age of 40. The plaques are also present in the normal aging brain, although at a lower number. These plaques are made up of the amyloid β peptide (β peptide) (Glenner and Wong, et al., Biochem. Biophys. Res. Comm. 120:885-890 (1984)), which is also the main protein constituent in cerebrovascular deposits and neurofibrillary tangles. The β peptide is a filamentous material that is arranged in beta-pleated sheets and has a molecular weight of 4.2-4.5 kd. It is a hydrophobic peptide comprising 39-42 amino acids. The determination of its amino acid sequence led to the cloning of the APP cDNA (Kang, et al., Nature 325:733-735 (1987); Goldgaber, et al., Science 235:877-880 (1987); Robakis et al., Proc. Natl. Acad. Sci. 84:4190-4194 (1987); Tanzi, et al., Nature 331:528-530 (1988) and genomic APP DNA (Lemaire et al., Nucl. Acids Res. 17:517-522 (1989); Yoshikai, et al., Gene 87, 257-263 (1990). Three forms of APP cDNAs (APP695, APP751, and APP770) have been isolated, and arise from a single precursor RNA by alternate splicing. The gene spans more than 175 Kb with 18 exons (Yoshikai, et al., 1990). APP contains three

-4-

cytoplasmic domain. The β peptide consists of 28 amino acids just outside the membrane and 14 residues of the hydrophobic transmembrane domain. Thus, the β peptide is a cleavage product of APP normally found in brain and other tissues such as heart, kidney and spleen. β peptide deposits, however, are usually found only in the brain, although Joachim et al., Nature 341:226-228 (1989) have reported β peptide deposits outside the brain in the skin, intestine, and subcutaneous tissues of most AD patients.

The larger alternate forms of APP (APP751, APP770) consist of all of APP695 plus one or two additional domains. APP751 consists of all of APP695 plus an additional 56 amino acids which has homology to the Kunitz family of serine protease inhibitors (KP1) (Tanzi et al., 1988; Weidemann, et al., Cell 57:115-126 (1989); Kitaguchi, et al., Nature 331:530-532 (1988); Tanzi et al., Nature 329, 156 (1987). APP770 contains APP751 and an additional 19 amino acid domain homologous to the neuron cell surface antigen OX-2 (Weidemann, et al., Cell 57:115-126 (1989); Kitaguchi et al., 1988). APP is post-translationally modified by the removal of the leader sequence and by the addition of sulfate and sugar groups.

Van Broeckhaven, et al., Science 248:1120-1122 (1990) have demonstrated that the APP gene is tightly linked to hereditary cerebral hemorrhage with amyloidosis (HCHWA-D) in two Dutch families. This was

-5-

of the full length protein (Goate, et al., (1991); Murrell et al., 1991; Chartier-Harlin et al., 1991). These mutations co-segregate with the disease within the families and are absent in families with late-onset AD.

There are no proven animal models to study AD, although aging nonhuman primates seem to develop amyloid plaques of β peptide in brain parenchyma and in the walls of some meningeal and cortical vessels. Although aged primates and canines can serve as animal models, they are expensive to maintain and need lengthy study periods. There are no spontaneous animal mutations with sufficient similarities to AD to be useful as experimental models. Various models have been proposed in which some AD-like symptoms may be induced by electrolysis, transplantation of AD brain samples, aluminum chloride, kainic acid or choline analogs (Kisner, et al., Neurobiol. Aging 7;287-292 (1986); Mistry, J.S., et al., J Med Chem 29;337-343 (1986)). Flood, et al. (Proc. Natl. Acad. Sci. 88:3363-3366 (1986)), reported amnesic effects in mice of four synthetic peptides homologous to the β peptide. Because none of these share with AD either common symptoms, biochemistry or pathogenesis, they are not likely to yield much useful information on etiology or treatment.

Transgenic mice with the human APP promoter linked to *E. coli* β -galactosidase (Wirak, D.O., et al., The EMBO J 10;289-296 (1991)) as well as transgenic mice expressing the human APP751 cDNA (Quon, D, et al. Nature 352, 239-241 (1991)) or subfragment of the cDNA including the β peptide (Wirak, D.O., et al., Science 253, 323-325 (1991); Sandhu, F.A., et al., J. Biol. Chem. 266, 21331-21334 (1991); Kawabata, S. Nature 354, 476-478 (1991)) have been produced. Results obtained in the different studies appear to depend upon the source of promoter

-6-

and the protein coding sequence used. For example, Wirak, et al. (1991) found that in transgenic mice expressing a form of the β peptide, intracellular deposits of "amyloid-like" material, reactive with antibodies prepared against APP were observed but did not find other histopathological disease symptoms. The intracellular nature of the antibody-reactive material and the lack of other symptoms suggest that this particular transgenic animal is not a faithful model system for Alzheimer's disease. Kawabata et al. (1991) report the production of amyloid plaques, neurofibrillary tangles, and neuronal cell death in their transgenic animals. In each of these studies, the same peptide fragment, the β peptide plus the 56 remaining C terminal amino acids of APP, was expressed. Wirak et al. (1991) used the human APP promoter while Kawabata, et al. (1991) used the human thy-1 promoter. In transgenic mice expressing the APP751 cDNA from the neuron-specific enolase promoter of Quon, D., et al., Nature 352, 239-241 (1991), extracellular deposits of material reactive with antibody prepared against APP were observed. What was not shown was whether the deposits contained full-length APP751 or β peptide or both, thus precluding

-7-

Alzheimer's disease is a complex syndrome involving pathological and behavioral aspects. A useful disease model should take these complexities into account. There are multiple proteins expressed from the gene with certain forms predominating in a given tissue. In the brain, the 695 form is predominant, but the mRNAs for additional forms are also present (Golde et al., Neuron 4; 253-267 (1990)). It is not known whether the ratio of the different forms changes with the age of the individual. The various protein forms result from alternative splicing such that the KI domain and/or the OX-2 domain may or may not be present in the mature protein. Moreover, the β -peptide results from post-translational processing of the precursor protein. This process can change in time as an individual ages, and can be affected by mutations not directly affecting the structure of the β -peptide: for example, the familial Alzheimer's disease (FAD) mutations at amino acid position 717 in the full length protein (Groate, et al., 1991; Murrell, et al., 1991; Chartier-Harlin, et al., 1991). Given these considerations, the production of universal animal models for Alzheimer's disease necessitates the construction of animal models that take into account the effects of known mutations on the phenotype resulting from the expression of these forms, and the possibility of the ratio of the

-8-

It is a still further object of the present invention to provide transgenic animals characterized by certain genetic abnormalities in the expression of the amyloid precursor protein.

Summary of the Invention

The construction of transgenic animal models for testing potential treatments for Alzheimer's disease is described. The models are characterized by a greater similarity to the conditions existing in naturally occurring Alzheimer's disease, based on the ability to control expression of one or more of the three forms of the β -amyloid precursor protein (APP), APP695, APP751, and APP770, or subfragments thereof, as well as various point mutations based on naturally occurring mutations, such as the FAD mutations at amino acid 717, and predicted mutations in the APP gene. The APP gene constructs are prepared using the naturally occurring APP promoter of human, mouse, or rat origin, as well as inducible promoters such as the mouse metallothionine promoter, which can be regulated by addition of heavy metals such as zinc to the animal's water or diet. Neuron-specific expression of constructs is achieved by using the rat neuron specific enolase promoter.

The constructs are introduced into animal embryos using standard techniques such as microinjection or embryonic stem cells. Cell culture based models can also be prepared by two methods. Cell cultures can be isolated from the transgenic animals or prepared from established cell cultures using the same constructs with standard cell transfection techniques.

The specific constructs that are described employ the following protein coding sequences: the APP770

-9-

construct; the APP751 cDNA and bearing a mutation at amino acid 717; the APP695 cDNA; the APP695 cDNA bearing a mutation at amino acid 717; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids with the addition of a mutation at amino acid 717; the APP leader sequence followed by the β peptide region; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP with the addition of a mutation at amino acid 717; a combination genomic-cDNA APP gene construct; and a combination genomic-cDNA APP gene construct, with the addition of a mutation at amino acid 717, operably linked to promoters selected from the following: the human APP gene promoter, mouse APP gene promoter, rat APP gene promoter, metallothionine gene promoter, rat neuron specific enolase gene promoter, human β actin gene promoter, human platelet derived growth factor B

-10-

replaced by the analogous human sequences; the endogenous mouse or rat APP gene modified through the process of homologous recombination between the APP gene in a mouse or rat ES cell and a vector carrying the human APP cDNA bearing a mutation at amino acid position 717 such that sequences in the resident rodent chromosomal APP gene beyond the recombination point (the preferred site for recombination is within APP exon 9) are replaced by the analogous human sequences bearing a mutation at amino acid 717. These constructs can be introduced into the transgenic animals and then combined by mating of animals expressing the different constructs.

The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's Disease as measured by their effect on the amount and histopathology of APP and β peptide in the animals, as well as by behavioral alterations.

Brief Description of the Drawings

The boxed portions of the drawings indicate the coding portions of the constructs. Filled

-11-

Figure 2b is a schematic of the APP751 cDNA coding sequence bearing a mutation at position 717.

Figure 3a is a schematic of the APP695 coding sequence.

Figure 3b is a schematic of the APP695 cDNA coding sequence bearing a mutation at position 717.

Figure 4a is a schematic of a coding sequence for the carboxy terminal portion of APP.

Figure 4b is a schematic of a coding sequence for the carboxy terminal portion of APP bearing a mutation at position 717.

Figure 5 is a schematic of a coding sequence for the β peptide portion of APP.

Figure 6a is a schematic of a combination genomic/cDNA coding sequence allowing alternative splicing of the KI and OX2 exons.

Figure 6b is a schematic of a combination genomic/cDNA coding sequence bearing a mutation at position 717 and allowing alternative splicing of the

-12-

Detailed Description of the Invention

The constructs and transgenic animals and animal cells are prepared using the methods and materials described below.

Sources of materials.

Restriction endonucleases are obtained from conventional commercial sources such as New England Biolabs (Beverly, MA.), Promega Biological Research Products (Madison, WI.), and Stratagene (LaJolla CA.), etc. Radioactive materials are obtained from conventional commercial sources such as Dupont/NEN or Amersham. Custom-designed oligonucleotides for site-directed mutagenesis are available from any of several commercial providers of such materials such as Bio-Synthesis Inc., Lewisville, TX. Kits for carrying out site-directed mutagenesis are available from commercial suppliers such as Promega Biological Research Products, Stratagene, etc. Clones of cDNA including the APP695, APP751, and APP770 forms of APP mRNA were obtained directly from Dr. Dmitry Goldgaber, NIH. Libraries of DNA are available from commercial providers such as Stratagene, La Jolla, CA., or Clontech, Palo Alto, CA. PC12 and 3T3 cells were obtained from ATCC (#CRL1721 and #CCL92 respectively). An additional PC12 cell line was obtained from Dr. Charles Marotta of Harvard Medical School, Massachusetts General Hospital, and McLean Hospital. Standard cell culture media appropriate to the cell line are obtained from conventional commercial sources such as Gibco/BRL. Murine stem cells, strain D3, were obtained from Dr. Rolf Kemler (Doetschman, et al., J. Embryol. Exp. Morphol. 87, 27 (1985)). Lipofectin for DNA transfection and the drug G418 for selection of stable transformants are available from Gibco/BRL.

-13-

Isolation of the human APP promoter.

A cosmid library, constructed from human placental DNA in the pWE15 cosmid vector, was screened by hybridization with a ^{32}P -labeled probe prepared by nick-translation (Maniatis, et al. Molecular Cloning: a laboratory manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989)) of the APP770 cDNA clone. Clones that hybridized with the probe were picked, purified, and characterized by restriction mapping, hybridization, and DNA sequencing. From one such clone containing a long 5' flanking region, a NotI to NruI restriction DNA fragment of approximately 25 kb was isolated. This fragment terminates 2 nucleotides before the initiator methionine codon of the Alzheimer's protein-coding region. This fragment, or a subfragment thereof, is the source of the human APP promoter for the constructs described herein. Analogous DNA fragments isolated using the same methods from mouse or rat genomic libraries are the source of mouse or rat promoters.

-14-

exons in the APP gene (Lemaire et al., Nucl. Acid Res, 17;517-522, 1989; Yoshikai et al., 1990). These results taken together indicate that the minimum size of the Alzheimer's gene is 175 kb.

I. Table of Alzheimer's Cosmid and Lambda Clones

<u>Library</u>	<u>Name of Clone</u>	<u>Insert Size (Kb)</u>	<u>Assigned APP Region</u>
1 Cosmid	1 GPAPP47A	35	25 Kb promoter & 9 Kb intron
	2 GPAAP36A	35	12 Kb promoter & 22 Kb intron
	3 GAPP30A 4GAPP43A	30-35 30-35	5' coding region exons 9, 10 and 11
Lambda	1 GAPP6A	12	exon 6
	2 GAPP6B	18	exons 4 and 5
	3 GAPP20A	20	exon 6
	4 GAPP20B	17	exons 4 and 5
	5 GAPP28A	18	exons 4 and 5
	6 GAPP3A	14	exon 6
	7 GAPP4A	19	exon 6
	8 GAPP10A	16	exons 9, 10 and 11
	9 GAPP16A	21	exon 6

Construction of Transgenes.

The clones bearing various portions of the human APP gene sequence shown in Figs. 1-5 are constructed in an analogous manner. First, the polyA addition signal from SV40 virus as a 253 base pair *Bcl*I to *Bam*HI fragment (Reddy et al., Science 200;494-502 (1978) is cloned into a modified vector from the pUC series. Next, the cDNA coding sequences (770, 751, or 695) are inserted. Correct orientation and content of the fragments inserted is determined through restriction endonuclease mapping and limited sequencing.

The clones bearing various carboxy terminal portions of the human APP gene sequence shown in Figs. 4 and 5 are constructed through several steps in

-15-

addition to those indicated above. First, an APP770 cDNA clone is digested with Asp718 which cleaves after position 56 (numbering system of Kang et al., 1987). The resulting 5' extension is filled in using the Klenow enzyme (Maniatis et al., 1989) and ligated to a hexanucleotide of the following sequence: AGATCT, the recognition site for BglII. After cleavage with BglII, which also cuts after position 1769, and re-ligation, the translational reading frame of the protein is preserved. The truncated protein thus encoded contains the leader sequence, followed by approximately 6 amino acids that precede the β peptide, followed by the β peptide, and the 56 terminal amino acids of APP. The clone in Fig. 5 is created by the introduction through site directed mutagenesis of nucleotide 1913 in the clone of Fig. 4a (numbering system of Kang et al., 1987) to a T thus creating a termination codon directly following the

... of the β peptide. Each of the

-16-

cDNA clone is converted to an *Xho*I site by site-directed mutagenesis. Cleavage of the resulting plasmid with *Xho*I cuts at the new *Xho*I site and a pre-existing site at 930, and releases the KI and OX-2 coding sequence.

The plasmid thus generated serves as the acceptor for the KI and OX-2 alternative splicing cassette. The alternative splicing cassette is created through a series of cloning steps. First, the *Taq*I site at position 860 (numbering system of Kang, et al., 1987) in the genomic clone containing exon 6 and adjacent downstream intron is converted to an *Xho*I site by site-directed mutagenesis. Cleavage of the resulting plasmid with *Xho*I cuts at the new *Xho*I site and an *Xho*I site within the adjacent intron. This fragment is cloned into the *Xho*I site in a plasmid vector. Second, the genomic clone containing exon 9 and adjacent upstream intron is cleaved with *Xho*I (position 930) and cloned into the *Xho*I site of a plasmid vector. These two junction exon/intron fragments are released from their respective plasmid backbones by cleavage with *Xho*I and either *Bam*HI or *Bgl*II, and cloned into the *Xho*I site of a plasmid vector. The resulting *Xho*I fragment is cleaved with either *Bam*HI or *Bgl*II and the genomic 6.6 kb *Bam*HI segment (Kitaguchi et al., 1988) containing the KI and OX-2 coding region along with their flanking intron sequences are inserted. After cleavage with *Xho*I, this DNA segment is inserted into the *Xho*I site of the modified APP770 cDNA constructed above. These cloning steps generate a combination cDNA/genomic expression clone that allows cells in a transgenic animal to

-17-

Activity of Gene Promoters.

Different promoter sequences are used to control expression of APP coding sequences. The ability to regulate expression of the APP gene in transgenic animals is believed to be useful in evaluating the roles of the different APP gene products in AD. The ability to regulate expression of the APP gene in cultured cells is believed to be useful in evaluating expression and processing of the different APP gene products and may provide the basis for cell cultured drug screens.

The metallothionine (MT) promoter is well characterized, has been employed in transgenic animals, and its expression can be regulated through modulation of zinc and glucocorticoid hormone levels (Palmiter et al., Nature 300, 611-615 (1982)).

The human APP promoter is also characterized with regard to expression in the CNS (Wirak et al., 1991). It is believed that this promoter is useful for accurately reproducing temporal and spatial expression of human APP sequences in the CNS of transgenic rodents. In addition to the human APP promoter, the APP promoter from mouse and rat is used in conjunction with the various wild-type and mutant APP coding sequences. Although the human APP promoter has been shown to have activity in the appropriate regions of the brain of transgenic mice (Wirak et al., 1991), it is believed that the use of a mouse APP promoter in a transgenic mouse or a rat APP promoter in a transgenic rat will offer an even more precise pattern of expression in the CNS of transgenic animals.

As an alternative for the control of human APP expression in neurons, the rat neuron specific enolase gene promoter is used. This promoter has been shown

-18-

Other alternatives for use in controlling human APP expression in neurons include the human β actin gene promoter (Ray et al., Genes and Development 5:2265-2273 (1991)), the human platelet derived growth factor B (PDGF-B) chain gene promoter (Sasahara et al., Cell 64:217-227 (1991)), the rat sodium channel gene promoter (Maue et al., Neuron 4:223-231 (1990)), the human copper-zinc superoxide dismutase gene promoter (Ceballos-Picot et al., Brain Res. 552:198-214 (1991)), and promoters for members of the mammalian POU-domain regulatory gene family (Xi et al., Nature 340:35-42 (1989)). The POU-domain is the region of similarity between the four mammalian transcription factors Pit-1, Oct-1, Oct-2, and unc-86, and represents a portion of the DNA-binding domain. These promoters are known or believed to result in expression specifically within the neurons of transgenic animals.

Expression of human APP in non-neuronal brain cells can be directed by the promoter for mouse myelin basic protein (Readhead et al., Cell 48:703-712 (1987)).

Yeast Artificial Chromosomes.

The constructs shown in Figure 7 are constructed as follows. Large segments of human genomic DNA, when cloned into certain vectors, can be propagated as autonomously-replicating units in the yeast cell. Such vector-borne segments are referred to as yeast artificial chromosomes (YAC; Burke et al. Science 236, 806 (1987)). A human YAC library is commercially available (Clontech, Palo Alto, CA) with an average insert size of 250,000 base pairs (range of 180,000 to 500,000 base pairs). A YAC clone of the Alzheimer's gene can be directly isolated by screening the library with the human APP770 cDNA. The inclusion of all of

-19-

The YAC-APP clone, shown in Figure 7a, is established in embryonic stem (ES) cells by selecting for neomycin resistance encoded by the YAC vector. ES cells bearing the YAC-APP clone are used to produce transgenic mice by established methods described below under "Transgenic Mice" and "Embryonic Stem Cell Methods". The YAC-APP gene bearing a mutation at amino acid 717 (Fig. 7b) is produced through the generation of a YAC library using genomic DNA from a person affected by a mutation at amino acid 717. The clone is identified and established in ES cells as described above.

Genetic Alteration of the Mouse APP Gene.

The nucleotide sequence homology between the human and murine Alzheimer's protein genes is approximately 85%. Within the β peptide-coding region, there are three amino acid differences between the two sequences. The val residue that is mutated at amino acid 717 is conserved between mouse, rat, and man. Wild-type rodents do not develop Alzheimer's disease nor do they develop deposits or plaques in their CNS analogous to those present in human Alzheimer's patients. Therefore, it is possible that the human but not the rodent form of β peptide is capable of causing disease. Homologous recombination (Capecchi, MR Science 244, 1288-1292 (1989)) can be used to convert the mouse Alzheimer's gene *in situ* to a gene encoding the human β peptide. This recombination is directed to a site downstream from the KI and OX-2 domains, for example, within exon 9,

that the natural alternative splicing mechanisms

-20-

vector is constructed from a human APP cDNA (695 or 770 form), either wild-type or mutant at amino acid 717. Cleavage of the recombination vector, for example, at the XhoI site within exon 9, promotes homologous recombination within the directly adjacent sequences (Capecchi, 1989). The endogenous APP gene resulting from this event is normal up to the point of recombination, within exon 9 in this example, and consists of the human cDNA sequence thereafter.

Mutant Forms of APP Proteins

Expression clones identical to these but bearing mutations at the amino acid 717 of the full length protein, the site of FAD mutations, are also constructed. Mutations at amino acid 717 are created by site-directed mutagenesis (Vincent, et al., 1989) and include mutations of the wild-type val codon to one of the following codons; ile, phe, gly, tyr, leu, ala, pro, trp, met, ser, thr, asn, gln. Mutations of val-717 to ile, phe, and gly, have been described (Goate et al., 1991; Murrell, et al., 1991; Chartier-harlin et al., 1991). None of these naturally-occurring mutations are charged or bulky amino acids. Therefore it is believed that replacement of val-717 with the other amino acids listed may also promote the FAD syndrome and have properties that are useful for animal AD models.

Preparation of Constructs for Transfections and Microinjections

... of ... injection are cleaved with

-21-

is redissolved in 1 ml of low salt buffer (0.2 M NaCl, 20 mM Tris™, pH 7.4, and 1 mM EDTA) and purified on an Elutip-D™ column. The column is first primed with 3 ml of high salt buffer (1 M NaCl, 20 mM Tris™, pH 7.4, and 1 mM EDTA) followed by washing with 5 ml of low salt buffer. The DNA solutions are passed through the column for three times to bind DNA to the column matrix. After one wash with 3 ml of low salt buffer, the DNA is eluted with 0.4 ml of high salt buffer and precipitated by two volumes of ethanol. DNA concentrations are measured by absorption at 260 nm in a UV spectrophotometer. For microinjection, DNA concentrations are adjusted to 3 µg/ml in 5 mM Tris™, pH 7.4 and 0.1 mM EDTA. Other methods for purification of DNA for microinjection are also described in Hogan, et al., Manipulating the mouse embryo (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1986), in Palmiter, et al., Nature 300, 611 (1982), in "The Qiagenologist, Application Protocols", 3rd edition, published by Qiagen, Inc., Chatsworth, CA., and in Maniatis, et al., Molecular Cloning: a laboratory manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989).

Construction of Transgenic Animals.

Animal Sources

Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan Sprague Dawley (Indianapolis, IN), etc. Swiss Webster female mice are preferred for embryo retrieval and transfer. B6D2F₁ males can be used for mating and vasectomized Swiss Webster studs can be used to stimulate pseudopregnancy. Vasectomized mice and rats can be obtained from the supplier.

Microinjection Procedures

The procedures for manipulation of the rodent

and microinjection of DNA are described in

-22-

detail in Hogan et al. Manipulating the mouse embryo, Cold Spring Harbor Laboratory, Cold Spring harbor, NY (1986), the teachings of which are incorporated herein.

Transgenic Mice

Female mice six weeks of age are induced to superovulate with a 5 IU injection (0.1 cc, ip) of pregnant mare serum gonadotropin (PMSG; Sigma) followed 48 hours later by a 5 IU injection (0.1 cc, ip) of human chorionic gonadotropin (hCG; Sigma). Females are placed with males immediately after hCG injection. Twenty-one hours after hCG, the mated females are sacrificed by CO₂ asphyxiation or cervical dislocation and embryos are recovered from excised oviducts and placed in Dulbecco's phosphate buffered saline with 0.5% bovine serum albumin (BSA; Sigma). Surrounding cumulus cells are removed with hyaluronidase (1 mg/ml). Pronuclear embryos are then washed and placed in Earle's balanced salt solution containing 0.5% BSA (EBSS) in a 37.5°C incubator with a humidified atmosphere at 5% CO₂, 95% air until the time of injection.

Randomly cycling adult female mice are paired with vasectomized males. Swiss Webster or other comparable strains can be used for this purpose. Recipient females are mated at the same time as donor females. At the time of embryo transfer, the recipient females are anesthetized with an intraperitoneal injection of 0.015 ml of 2.5% avertin per gram of body weight. The oviducts are exposed by a single midline dorsal incision. An incision is then made through the body wall directly over the oviduct. The ovarian bursa is then torn with watchmakers forceps. Embryos to be transferred are placed in DPBS and in the tip of a transfer pipet (about 10-12 embryos). The pipet tip is inserted into the infundibulum and the embryos

-23-

transferred. After the transfer, the incision is closed by two sutures.

Transgenic Rats

The procedure for generating transgenic rats is similar to that of mice (Hammer et al., Cell 63:1099-112 (1990)). Thirty day-old female rats are given a subcutaneous injection of 20 IU of PMSG (0.1 cc) and 48 hours later each female placed with a proven male. At the same time, 40-80 day old females are placed in cages with vasectomized males. These will provide the foster mothers for embryo transfer. The next morning females are checked for vaginal plugs. Females who have mated with vasectomized males are held aside until the time of transfer. Donor females that have mated are sacrificed (CO₂ asphyxiation) and their oviducts removed, placed in DPBS (Dulbecco's phosphate buffered saline) with 0.5% BSA and the embryos collected. Cumulus cells surrounding the embryos are removed with hyaluronidase (1 mg/ml). The embryos are then washed and placed in EBSS (Earle's balanced salt solution) containing 0.5% BSA in a 37.5°C incubator until the time of microinjection.

Once the embryos are injected, the live embryos are moved to DPBS for transfer into foster mothers. The foster mothers are anesthetized with ketamine (40 mg/kg, ip) and xylazine (5 mg/kg, ip). A dorsal midline incision is made through the skin and the ovary and oviduct are exposed by an incision through the muscle layer directly over the ovary. The ovarian bursa is torn, the embryos are picked up into the transfer pipet, and the tip of the transfer pipet is inserted into the infundibulum. Approximately 10-12 embryos are transferred into each rat oviduct through the infundibulum. The incision is then closed with sutures, and the foster mothers are housed singly.

-24-

Embryonic Stem (ES) Cell MethodsIntroduction of cDNA into ES cells:

Methods for the culturing of ES cells and the subsequent production of transgenic animals, the introduction of DNA into ES cells by a variety of methods such as electroporation, calcium phosphate/DNA precipitation, and direct injection are described in detail in Teratocarcinomas and embryonic stem cells, a practical approach, ed. E.J. Robertson, (IRL Press 1987), the teachings of which are incorporated herein. Selection of the desired clone of transgene-containing ES cells is accomplished through one of several means. In cases involving random gene integration, an APP clone is co-precipitated with a gene encoding neomycin resistance. Transfection is carried out by one of several methods described in detail in Lovell-Badge, in Teratocarcinomas and embryonic stem cells, a practical approach, ed. E.J. Robertson, (IRL Press 1987) or in Potter et al Proc. Natl. Acad. Sci. USA 81, 7161 (1984). Calcium phosphate/DNA precipitation,

-25-

DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination, described by Capecchi, (1989). Direct injection results in a high efficiency of integration. Desired clones are identified through PCR of DNA prepared from pools of injected ES cells. Positive cells within the pools are identified by PCR subsequent to cell cloning (Zimmer and Gruss, Nature 338, 150-153 (1989). DNA introduction by electroporation is less efficient and requires a selection step. Methods for positive selection of the recombination event (i.e., neo resistance) and dual positive-negative selection (i.e., neo resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described by Joyner et al., Nature 338, 153-156 (1989) and Capecchi, (1989), the teachings of which are incorporated herein.

Embryo Recovery and ES cell Injection

Naturally mating or superovulated female mice

-26-

Recipient females are mated such that they will be at 2.5 to 3.5 days post-mating when required for implantation with blastocysts containing ES cells. At the time of embryo transfer, the recipient females are anesthetized with an intraperitoneal injection of 0.015 ml of 2.5% avertin per gram of body weight. The ovaries are exposed by making an incision in the body wall directly over the oviduct and the ovary and uterus are externalized. A hole is made in the uterine horn with a 25 gauge needle through which the blastocysts are transferred. After the transfer, the ovary and uterus are pushed back into the body and the incision is closed by two sutures. This procedure is repeated on the opposite side if additional transfers are to be made.

Identification of Transgenic Mice and Rats.

Tail samples (1-2 cm) are removed from three week old animals. DNA is prepared and analyzed by both Southern blot and PCR to detect transgenic founder (F_0) animals and their progeny (F_1 and F_2).

Pathological Studies

The various F_0 , F_1 , and F_2 animals that carry the microinjected transgene are sacrificed by CO_2 asphyxiation and analyzed by immunohistology for neuritic plaques and neurofibrillary tangles (NFTs) in the brain. Brains of mice and rats from each transgenic line are fixed in 4% paraformaldehyde and sectioned on a cryostat. Sections are stained with antibodies reactive with the APP and/or the β peptide. Secondary antibodies conjugated with fluorescein, rhodamine, horse radish peroxidase, or alkaline phosphatase are used to detect the primary antibody. These experiments permit identification of amyloid plaques and the regionalization of these plaques to

-27-

observed in deeper grey matter including the amygdaloid nucleus, corpus striatum and diencephalon. Sections are also stained with other antibodies diagnostic of Alzheimer's plaques, recognizing antigens such as Alz-50, tau, A2B5, neurofilaments, neuron-specific enolase, and others that are characteristic of Alzheimer's plaques (Wolozin, et al., Science 232, 648 (1986); Hardy and Allsop, Trends in Pharm. Sci. 12, 383-388 (1991); Selkoe, Ann. Rev. Neurosci. 12, 463-490 (1989); Arai et al., Proc. Natl. Acad. Sci. USA 87, 2249-2253 (1990); Majocha et al., Amer. Assoc. Neuropathology Abs; 99,22 (1988); Masters et al., Proc. Natl. Acad. Sci. 82,4245-4249; Majocha et al., Can J Biochem Cell Biol 63;577-584 (1985)). Staining with thioflavins and congo red is also carried out to analyze co-localization of β peptide deposits within neuritic plaques and NFTs.

Analysis of APP and β Peptide Expression:

mRNA: mRNA is isolated by the acid guanidinium thiocyanate-phenol:chloroform extraction method

-28-

The protein fractions are denatured in Laemmli sample buffer and electrophoresed on SDS-Polyacrylamide gels. The proteins are then transferred to nitrocellulose filters by electroblotting. The filters are blocked, incubated with primary antibodies, and finally reacted with enzyme conjugated secondary antibodies. Subsequent incubation with the appropriate chromogenic substrate reveals the position of APP proteins.

Pathological and Behavioral Studies

Pathological Studies

Immunohistology and thioflavin S staining are conducted as described elsewhere herein.

In situ Hybridizations: Radioactive or enzymatically labeled probes are used to detect mRNA *in situ*. The probes are degraded approximately to 100 nucleotides in length for better penetration of cells. The procedure of Chou et al. J. Psych. Res. 24,27-50 (1990) for fixed and paraffin embedded samples is briefly described below although similar procedures can be employed with samples sectioned as frozen material. Paraffin slides for *in situ* hybridization are dewaxed in xylene and rehydrated in a graded series of ethanols and finally rinsed in phosphate buffered saline (PBS). The sections are post-fixed in fresh 4% paraformaldehyde. The slides are washed with PBS twice for 5 minutes to remove paraformaldehyde. Then the sections are permeabilized by treatment with a 20 µg/ml proteinase K solution. The sections are re-fixed in 4% paraformaldehyde, and basic molecules that could give rise to background probe binding are acetylated in a 0.1 M triethanolamine, 0.3 M acetic anhydride solution for 10 minutes. The slides are washed in PBS, then dehydrated in a graded series of ethanols and air dried. Sections are hybridized with antisense probe, using sense probe as a control. After appropriate washing, bound radioactive probes

-29-

are detected by autoradiography or enzymatically labeled probes are detected through reaction with the appropriate chromogenic substrates.

Behavioral Studies

Behavioral tests designed to assess learning and memory deficits are employed. An example of such as test is the Morris Water maze (Morris, Learn Motiv. 12;239-260 (1981)). In this procedure, the animal is placed in a circular pool filled with water, with an escape platform submerged just below the surface of the water. A visible marker is placed on the platform so that the animal can find it by navigating toward a proximal visual cue. Alternatively, a more complex form of the test in which there are no formal cues to mark the platform's location will be given to the animals. In this form, the animal must learn the platform's location relative to distal visual cues.

The procedures applied to test transgenic mice is similar for transgenic rats.

Screening of Compounds for Treatment of Alzheimer's Disease

The transgenic animals and animal cells are used to screen compounds for a potential effect in the treatment of Alzheimer's disease using standard methodology. The compound is administered to the animals or introduced into the culture media over a period of time and in various dosages, then the animals or animal cells examined for alterations in APP expression, histopathology, and/or behavior using the procedures described above.

Example 1: Expression of pMTAPP-1 in NIH3T3 and PC12 Cells.

The clone, pMTAPP-1 is an example of the expression vector shown in Fig. 1a where the promoter used is the metallothionin promoter. Stable cell lines were derived by transfecting NIH3T3 and PC12 cell lines (ATCC #CCL92 and CRL1721). 0.5×10^6 of

-30-

NIH3T3 or PC12 cells were plated into 100 mm dishes and transfected with a mixture of 5 mg of the SalI fragment and 1 mg of pSV2neo DNA (46) precipitated in the presence of 50 mg lipofectin (Gibco, BRL) in a final volume of 100 μ l. Polylysine-coated plates were used for PC12 cells, which normally do not adhere well to tissue culture dishes. The cells were fed with selection medium containing 10% fetal bovine serum in DMEM or RPMI and supplemented with G418. Five hundred mg/ml (biological weight) and 250 mg/ml of G418 were used to select colonies from NIH3T3 and PC12 cells, respectively. Fifteen days after transfection, colonies of cells resistant to G418 were isolated by cloning rings and expanded in T flasks. The presence of APP cDNA in the cells was detected by PCR using the procedure of Mullis and Faloona, Methods Enzymol. 155;335-350 (1987), the teachings of which are incorporated herein.

Expression of APP in 25 colonies from each cell line was analyzed by immunostaining (Majocha et al., 1988). Cells were grown to subconfluence and fixed in a solution containing 4% paraformaldehyde, 0.12 M NaCl, and 20 mM Na_3PO_4 , pH 7.0. They were incubated overnight with a primary monoclonal antibody against a synthetic β peptide sequence (Masters et al., 1985) provided by Dr. Ronald Majocha, Massachusetts General Hospital, Boston, MA, followed by a generalized anti-mouse antibody conjugated to biotin (Jackson ImmunoResearch Labs, PA). Immunostaining was then performed by adding avidin-horseradish peroxidase (HRP) (Vector Labs, Burlingame, CA) and diaminobenzidine as the chromogen (Majocha et al., 1985). The results indicated that the pMTAPP-1 vector was expressing APP in both NIH3T3 and PC12 cells.

Example 2: Expression of pEAPP-1 in PC12 Cells.

pEAPP-1 is an example of the 25 kb human APP gene promoter linked to and controlling expression of a

-31-

human APP770 cDNA like the construct in Figure 1A. DNA from this construct was transfected into PC12 cells as described above. Certain clones of pEAPP-1 transfected cells exhibited a differentiation phenotype morphologically similar to that exhibited by PC12 cells treated with nerve growth factor (NGF). PC12 cells normally are fairly round and flat cells. Those transfected with pEAPP-1 have cytoplasmic extensions resembling neurites. PC12 cells treated with NGF extend very long neuritic extensions. Thirteen PC12 cell clones transfected with pEAPP-1 were selected and propagated. Eight of these cell clones exhibited the spontaneous differentiation phenotype with clones 1-8, 1-1, and 1-4 exhibiting the strongest phenotypes. Staining of pEAPP-1 transfected PC12 cells with antibody against the β peptide as described above indicated that those cells exhibiting the differentiation were also expressing APP. Because PC12 cells transfected with the pMTAPP1 clone did not exhibit this phenotype even though the APP770 cDNA is expressed, these results suggest that expression of APP770 from the human promoter has novel properties regarding the physiology of the cell.

Example 3: Expression of pMTA4 in PC12 Cells.

pMTA4 is an example of the type of construct shown in Figure 4A where the promoter used is the metallothionine promoter. The protein encoded by this construct differs slightly from that depicted in Figure 4. An APP770 cDNA clone was digested with Asp718 which cleaves after position 56 (number system of Kang, et al., 1987). The resulting 5' extension was filled in using the Klenow enzyme (Maniatis). The same DNA preparation was also cleaved with EcoRI which also cuts after position 1795 and the resulting 5' extension was filled in using the Klenow enzyme (Maniatis). Self-ligation of this molecule results in an expression clone in which the truncated protein

-32-

thus encoded contains the leader sequence, followed by a shortened version of the β peptide starting with the sequence phe-arg-val-gly-ser-of the β peptide followed by the 56 terminal amino acids of APP. DNA from this construct was transfected into PC12 cells as described above.

Example 4: **Generation of Transgenic Mice expressing APP under the control of the MT-1 promoter.**

Transgenic mice were made by microinjecting pMTAPP1 vector DNA into pronuclear embryos. pMTAPP1 is an example of the type of construct shown in Fig. 1a which is operably linked to the metallothioneine promoter. The procedures for microinjection into mouse embryos are described in "Manipulating the mouse embryo" by B. Hogan et al. (1986). Only a brief description of the procedures is described below.

Mice were obtained from Taconic Laboratories (German Town, New York). Swiss Webster female mice were used for embryo retrieval and implantation. B6D2F₁ males were used for mating and vasectomized Swiss webster studs were used to simulate pseudopregnancy.

Embryo Recovery: Female mice, 4 to 8 weeks of age, were induced to superovulate with 5 IU of pregnant mare's serum gonadotropin (PMSG; Sigma) followed 48 hours later by 5 IU of human chorionic gonadotropin (hCG; Sigma). Females were placed with males immediately after hCG injection. Embryos were recovered from excised oviducts of mated females 21 hours after hCG in Dulbecco's phosphate buffered saline with 0.5% bovine serum albumin (BSA; Sigma). Surrounding cumulus cells were removed with hyaluronidase (1 mg/ml). Pronuclear embryos were then washed and placed in Earle's balanced salt solution at 37.5°C incubator with

-33-

a humidified atmosphere at 7% CO₂, 5% O₂, and 88% N₂ until the time of injection.

Microinjection: Elutip-D™ purified SalI DNA was dissolved in 5 mM Tris (pH 7.4) and 0.1 mM EDTA at 3 µg/ml concentration for microinjection. Microneedles and holding pipettes were pulled from Fisher coagulation tubes (Fisher) on a DKI model 720 pipette puller. Holding pipettes were then broken at approximately 70 µm (O.D.) and fire polished to an I.D. of about 30 µm on a Narishige microforge (model MF-83). Pipettes were mounted on Narishige micromanipulators which were attached to a Nikon Diaphot microscope. The air-filled injection pipette was filled with DNA solution through the tip after breaking the tip against the holding pipette. Embryos, in groups of 30 to 40, were placed in 100 µl drops of EBBS under paraffin oil for micromanipulation. An embryo was oriented and held

the injection pipette was

-34-

infundibulum and embryos were transferred. After the transfer, the incision was closed by two sutures.

Analysis Of Mice For Transgene Integration: At three weeks of age tail samples about 1 cm long were excised for DNA analysis. The tail samples were digested by incubating with shaking overnight at 55°C in the presence of 0.7 ml 5 mM Tris, pH 8.0, 100 mM EDTA, 0.5% SDS and 350 µg of proteinase K. The digested material was extracted once with an equal volume of phenol and once with an equal volume of phenol:chloroform (1:1 mixture). The supernatants were mixed with 70 µl 3 M sodium acetate (pH 6.0) and the DNAs were precipitated by adding equal volume of 100% ethanol. The DNAs were spun down in a microfuge, washed once with 70% ethanol, dried and dissolved in 100 µl TE buffer (10 mM tris pH 8.0 and 1 mM EDTA).

10-20 µl of DNAs were restricted with BamHI, electrophoresed on 1% agarose gels, blotted onto nitrocellulose paper, and hybridized with ³²P-labeled

-35-

We claim:

1. A non-human transgenic mammal or mammalian cells containing a construct selected from the group consisting of the APP770 cDNA; the APP770 cDNA bearing a mutation at amino acid 717; the APP751 cDNA containing the KI protease inhibitor domain without the OX2 domain in the construct; the APP751 cDNA bearing a mutation at amino acid 717; the APP695 cDNA; the APP695 cDNA bearing a mutation at amino acid 717; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids with the addition of a mutation at amino acid 717; APP leader sequence followed by the β peptide region; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP with the addition of a mutation at amino acid 717; a combination genomic-cDNA APP gene construct; a combination genomic-cDNA APP gene construct, with the addition of a mutation at amino acid 717, operably linked to a promoter selected from the following: the human APP promoter, mouse APP promoter; rat APP promoter, metallothionine promoter, rat neuron specific enolase promoter, human β actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter; and combinations thereof.

2. The transgenic mammal of claim 1 expressing any of the constructs.

3. Cells cultured from the transgenic mammal of claim 1.

-36-

4. The mammal of claim 1 produced by introduction of the construct into an embryo, insertion of the embryo into a surrogate mother, and allowing the embryo to develop to term.

5. The mammal of claim 1 wherein the mammal is a rodent.

6. The mammal of claim 1 produced by mating transgenic mammals expressing different constructs.

7. The mammal of claim 1 wherein the codon encoding the val amino acid residue at 717 in the wild type APP gene is mutated to encode an amino acid selected from the group consisting of ile, phe, gly, tyr, leu, ala, pro, trp, met, ser, thr, asn, and gln.

8. The mammal of any of claim 1 wherein the promoter is the APP promoter of the same species of origin as the mammal.

9. A method for making a transgenic model for Alzheimer's disease comprising introducing into non-human mammalian cells or embryos a construct selected from the group consisting of the APP770 cDNA; the APP770 cDNA bearing a mutation at amino acid 717; the APP751 cDNA containing the KI protease inhibitor domain without the OX2 domain in the construct; the APP751 cDNA bearing a mutation at amino acid 717; the APP695 cDNA; the APP695 cDNA bearing a mutation at amino acid 717; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino acids with the addition of a mutation at amino acid 717; APP leader sequence followed by the β peptide region; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP; the β peptide region plus the remaining carboxy terminal 56 amino acids of APP with the addition of a mutation at amino acid 717; a combination genomic-cDNA APP gene construct; a

-37-

combination genomic-cDNA APP gene construct, with the addition of a mutation at amino acid 717, operably linked to a promoter selected from the following: the human APP promoter, mouse APP promoter, rat APP promoter, metallothionine promoter, rat neuron specific enolase promoter, human β actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter; and combinations thereof.

10. The method of claim 9 wherein the transgenic model is a mammal having altered behavior.

11. A method for screening compounds for an effect on Alzheimer's disease comprising

exposing a transgenic mammal or mammalian cells containing a construct selected from the group consisting of the APP770 cDNA; the APP770 cDNA bearing a mutation at amino acid 717; the APP751 cDNA containing the KI protease inhibitor domain without the OX2 domain in the construct; the APP751 cDNA bearing a mutation at amino acid 717; the APP695 cDNA; the APP695 cDNA bearing a mutation at amino acid 717; the APP leader sequence followed by the β peptide region plus the remaining carboxy terminal 56 amino

-38-

acid 717, operably linked to a promoter selected from the following: the human APP promoter, mouse APP promoter, rat APP promoter, metallothionine promoter, rat neuron specific enolase promoter, human β actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter; transgenic animals or animal cells containing a construct selected from the group consisting of a human yeast artificial chromosome construct controlled by the human APP promoter and a human yeast artificial chromosome construct controlled by the human APP promoter with the addition of a mutation at amino acid 717, and transgenic animals or animal cells containing an APP gene selected from the group consisting of the endogenous mouse or rat APP gene modified such that sequences in the resident chromosomal APP gene beyond the recombination point in APP exon 9 are replaced by the analogous human sequences and the analogous human sequences with the addition of a mutation at amino acid 717; and combinations thereof, to the compound to be tested and determining if there is altered expression of APP.

12. The method of claim 11 using transgenic mammals further comprising determining if there is

1/3

 KI domain  B peptide

 OX2 domain  Leader sequence




FIG. 4a




FIG. 4b




FIG. 5





FIG. 6a



FIG. 6b






FIG. 7a




FIG. 7b




FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 92/11276

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C12N 15/00, A01K 67/027, C12N 5/10, C07K 15/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: C12N, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9119810 (CALIFORNIA BIOTECHNOLOGY INC.), 26 December 1991 (26.12.91), figures 4-7, claims 1-4, pages 10-13, 15-16, 29-33, 61 and 64-65, examples 4-8, page 60, line 10 - page 61	1-6,9-13
Y	--	1-13
Y	Nature, Volume 352, July 1991, D. Quon et al., "Formation of beta-amyloid protein deposits in brains of transgenic mice", page 239 - page 241, page 239, page 241 left column	1-13
	--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

- * Special categories of cited documents:
- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 April 1993

13.05.93

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. J1 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Carl Olof Gustafsson

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 92/11276

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Current opinion in neurology and neurosurgery, Volume 5, 1992, B. T. Hyman et al., "Amyloid, dementia and Alzheimer's disease", page 88 - page 93, fig 2, page 88, right column - page 89, left column, page 90, right column	1-13
Y	--	1-13
X	Journal of Biological Chemistry, Volume 266, No 32, November 1991, F. A. Sandhu et al., "Expression of the Human beta-Amyloid Protein of Alzheimer's Disease Specifically in the Brains of Transgenic Mice", pages 21331-21334, Fig 1, page 21334	1-6,9,10
Y	--	1-13
X	WO, A1, 8906689 (THE MCLEAN HOSPITAL CORPORATION), 27 July 1989 (27.07.89), page 21, line 18 - line 20; page 40 - page 46, figure 8, page 40, last paragraph	1,9
X	Nature, Volume 354, December 1991, S. Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein", page 476 - page 478, figure 1, page 478	1-6,9-13
X	EP, A1, 0451700 (D. O. WIRAK), 16 October 1991 (16.10.91), page 6, line 35 - page 7, line 5; page 10 - page 13, examples 11-16	1-6,9-13
X	Science, Volume 253, July 1991, D. O. Wirak et al., "Deposits of Amyloid beta Protein in the Central Nervous System of Transgenic Mice", page 323 - page 325, page 323	1,9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/11276

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The EMBO Journal, Volume 10, No 2, 1991, D. O. Wirak et al., "Regulatory region of human amyloid precursor protein (APP) gene promotes neuron-specific gene expression in the CNS of transgenic mice", page 289 - page 296, figure 2, Discussion --	1-13
Y	Nature, Volume 349, February 1991, A. Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease" page 704 - page 706 --	1,7,9,11
Y	Nature, Volume 353, October 1991, M-C. Chartier-Harlin et al., "Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene" page 844 - page 846 --	1,7,9,11
Y	Science, Volume 254, October 1991, J. Murrell et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease" --	1,7,9,11
P,X	WO, A, 9206187 (THE UPJOHN COMPANY), 16 April 1992 (16.04.92), page 8, line 15 - line 33, examples 1 and 2 --	1-6,8-13
P,X	WO, A, 9213069 (IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE), 6 August 1992 (06.08.92), claims, examples 3 and 4, pages 10, 11, 13, 14 and 19-21 --	1-13
E,X	WO, A1, 9302189 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA), 4 February 1993 (04.02.93), claims, example -- -----	1-5,9,11-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/11276

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The present application lacks unity of invention a posteriori - see the cited documents. Thus, each of the claimed solutions in claims 1, 9 and 11 to the known problem of creating a transgenic animal model for Alzheimers disease, represents a separate inventive concept.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

S, .9144

INTERNATIONAL SEARCH REPORT
Information on patent family members

31/03/93

International application No.
PCT/US 92/11276

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO-A1-	9119810	26/12/91	AU-A-	8210291	07/01/92
WO-A1-	8906689	27/07/89	AU-A-	3056289	11/08/89
EP-A1-	0451700	16/10/91	NONE		
WO-A-	9206187	16/04/92	AU-A-	8768191	28/04/92
WO-A-	9213069	06/08/92	AU-A-	1169492	27/08/92
WO-A1-	9302189	04/02/93	NONE		